{
    "id": 22971,
    "fullName": "AREG dec exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "AREG dec exp indicates a decreased expression of the Areg protein. However, the mechanism causing the decreased expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 374,
        "geneSymbol": "AREG",
        "terms": [
            "AREG",
            "AR",
            "AREGB",
            "CRDGF",
            "SDGF"
        ]
    },
    "variant": "dec exp",
    "createDate": "05/26/2016",
    "updateDate": "08/17/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6531,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I trial, the combination of Camptosar (irinotecan) and Vectibix (panitumumab) treatment in RAS wild-type colorectal cancer patients with decreased expression of AREG and EREG resulted in a similar PFS (3.2 mo vs 4.0 mo) when compared to Camptosar (irinotecan) alone (PMID: 26867820).",
            "molecularProfile": {
                "id": 23614,
                "profileName": "AREG dec exp EREG dec exp"
            },
            "therapy": {
                "id": 4138,
                "therapyName": "Irinotecan + Panitumumab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 5687,
                    "pubMedId": 26867820,
                    "title": "Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26867820"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16100,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III clinical trial (AIO KRK-0207), lower AREG mRNA levels in BRAF and KRAS wild-type metastatic colorectal cancer patients (n=122) were associated with shorter overall survival following first-line therapy of combined Eloxatin (oxaliplatin), Avastin (bevacizumab), and fluoropyrimidine (either Xeloda (capecitabine) or Adrucil (fluorouracil) plus Wellcovorin (leucovorin)) and maintenance with Avastin (bevacizumab) (PMID: 30467535; NCT00973609).",
            "molecularProfile": {
                "id": 31535,
                "profileName": "AREG dec exp BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 1484,
                "therapyName": "Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin",
                "synonyms": "Bevacizumab + FOLFOX"
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14233,
                    "pubMedId": 30467535,
                    "title": "Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30467535"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16098,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase III clinical trial (AIO KRK-0207), lower AREG mRNA levels in BRAF and KRAS wild-type metastatic colorectal cancer patients (n=122) were associated with shorter overall survival following first-line therapy of combined Eloxatin (oxaliplatin), Avastin (bevacizumab), and fluoropyrimidine (either Xeloda (capecitabine) or Adrucil (fluorouracil) plus Wellcovorin (leucovorin)) and maintenance with Avastin (bevacizumab) (PMID: 30467535; NCT00973609).",
            "molecularProfile": {
                "id": 31535,
                "profileName": "AREG dec exp BRAF wild-type KRAS wild-type"
            },
            "therapy": {
                "id": 1601,
                "therapyName": "Bevacizumab + Capecitabine + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 14233,
                    "pubMedId": 30467535,
                    "title": "Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients-Analysis of the Phase III AIO KRK-0207 Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30467535"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "molecularProfiles": [
        {
            "id": 23612,
            "profileName": "AREG dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23614,
            "profileName": "AREG dec exp EREG dec exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31535,
            "profileName": "AREG dec exp BRAF wild-type KRAS wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}